View Clinical Trial (Medical Research Study)
Respiratory and Autonomic Plasticity Following Intermittent Hypoxia - NCT00860743-48201(Clinical Trial 277986)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Detroit |
|
State:
|
|
MI |
| Zip Code: |
|
48201 |
| Conditions: |
|
Sleep Apnea Syndromes |
| Purpose: |
|
The prevalence of obstructive sleep apnea is high in the Veteran population. If not treated
promptly, sleep apnea may result in daytime fatigue which may lead to increased prevalence
of accidents while driving or in the workplace. Recent large scale epidemiological studies
have shown that the prevalence of excessive daytime sleepiness increases in individuals who
suffer from obstructive sleep apnea. Obstructive sleep apnea may also result in the
development of hypertension and other cardiovascular disorders. Previous findings have shown
that subjects with sleep apnea have a greater risk for developing coronary vascular disease
compared to individuals that do not suffer from sleep apnea Thus, a significant amount of
evidence suggests that sleep apnea is a major health concern in the Veteran population.
Consequently, determining the mechanisms that may impact on the severity of sleep apnea and
increase the prevalence of cardiovascular incidents associated with this disorder is
important, as is discovering novel treatments.
|
| Study summary: |
|
Approximately 8 % of the Veteran population in the United States suffers from sleep apnea.
Consequences of untreated sleep apnea include increased daytime fatigue, hypertension and
stroke. Thus, sleep apnea is a major health concern. One of the primary hallmarks of sleep
apnea is exposure to intermittent hypoxia (IH) which occurs as a consequence of central or
obstructive apneas. Exposure to IH may lead to neural plasticity (i.e. a change in system
performance based on prior experience) of the respiratory and autonomic nervous system. One
adaptation that has been shown to manifest itself in animals following exposure to IH is
long-term facilitation (LTF) of ventilation and sympathetic nervous system activity (SNSA).
This phenomenon is characterized by a gradual increase in respiratory motor activity and
SNSA during successive periods of normoxia that separate hypoxic episodes and by activity
that persists above baseline levels for up to 90 minutes following exposure to IH. Although
LTF of minute ventilation has been well established in animals it has not been observed
consistently in healthy humans or in individuals with obstructive sleep apnea. Similarly,
although a few studies have shown that exposure to IH leads to increases in SNSA in healthy
individuals the magnitude of the response has varied significantly. Findings from animal
studies suggest that the manifestation of LTF in humans might in part be dependent on a
variety of factors, including prior exposure to IH, arousal state (wake vs. sleep) and
gender. Thus, the initial aim of our proposal will establish whether LTF can be induced in
healthy humans and individuals with obstructive sleep apnea and whether the magnitude of the
response is dependent on those factors mentioned above. Moreover, the initial aim will
explore whether the presence of LTF of minute ventilation promotes or mitigates apnea
severity. Animal studies have also indicated that LTF of respiratory and autonomic activity
may in part be induced by increases in oxidative stress. Thus, the second objective of our
proposal will explore whether administration of an antioxidant cocktail impacts respiratory
and autonomic nervous system plasticity during wakefulness and sleep following IH. Likewise,
the second aim will explore whether administration of an antioxidant cocktail alters apnea
severity following exposure to IH. Establishing whether LTF of minute ventilation exists in
individuals with sleep apnea is important since activation of this phenomenon could impact
on apnea severity across the night. Similarly, LTF of SNSA activity and possibly long-term
depression (LTD) of parasympathetic nervous system activity (PNSA) could ultimately lead to
persistent increases in blood pressure and heart rate. Furthermore, given that exposure to
IH may lead to long-term plasticity of respiratory and autonomic activity that are
physiologically detrimental, exploring mechanisms that ultimately lead to treatments that
may mitigate or prevent the manifestation of this phenomenon are important. |
| Criteria: |
|
Inclusion Criteria:
Characteristics of OSA subject population:
1. Body mass index < 30 kg/m2.
2. 20 to 40 years old.
3. Newly diagnosed never-treated mild to moderate sleep apnea (i.e. 50 > apnea/hypopnea
index >10 events per hour - average nocturnal oxygen saturation > 90%).
4. Not pregnant.
5. Free of any other known medical conditions.
6. Not taking any medication.
7. Non-smokers with normal lung function.
8. Minimal alcohol consumption (i.e. no more than the equivalent of a glass of
wine/day).
Characteristics of control group population:
1. Body mass index < 30 kg/m2.
2. 20 to 40 years old.
3. Apnea/hypopnea index < 5 events per hour.
4. Not pregnant.
5. Free of any known medical conditions.
6. Not taking any medication.
7. Non-smokers with normal lung function.
8. Minimal alcohol consumption (i.e. no more than the equivalent of a glass of
wine/day).
Exclusion Criteria:
Anything not in inclusion criteria. |
|
|
|
| Study is available at: |
|
John D. Dingell VA Medical Center, Detroit Detroit, MI 48201 United States
Primary Contact: Jason H Mateika, PhD Email: jmateika@med.wayne.edu Phone: 313-576-4481
Secondary Contact: Jason H Mateika, PhD Email: jmateika@med.wayne.edu Phone: (313) 576-4481 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|